Dulaglutide
A once-weekly GLP-1 analog used for blood-sugar control, with demonstrated cardiovascular benefit.
FDA-approved as Trulicity (type 2 diabetes).
Look it up on Wikipedia4 listings across 2 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
FDA-approved (Trulicity). It's a biologic-sized fusion protein; compounded versions aren't a recognised option.
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Huatai Peptide #15 by metascore · China |
Metascore 85Finnrick 72%Bought vials 97% of label · 12 testsTitrateLabNo report for thisConfirmed with lab: 15 of 15Online checkout |
Dulaglutide 10Bottlex10mg | 10 × 10 mg = 100 mg | $209.00 $20.90 per vial |
$2.09 | Buy |
Huatai Peptide #15 by metascore · China |
Metascore 85Finnrick 72%Bought vials 97% of label · 12 testsTitrateLabNo report for thisConfirmed with lab: 15 of 15Online checkout |
Dulaglutide 10Bottlex5mg | 10 × 5 mg = 50 mg | $121.00 $12.10 per vial |
$2.42 | Buy |
Hangzhou Youngpeptide Biotechnology HYB #153 by metascore |
Dulaglutide 10 mg – 10 Vials | 10 × 10 mg = 100 mg | $290.00 $29.00 per vial |
$2.90 | Buy | |
Hangzhou Youngpeptide Biotechnology HYB #153 by metascore |
Dulaglutide 5 mg – 10 Vials | 10 × 5 mg = 50 mg | $180.00 $18.00 per vial |
$3.60 | Buy |
Mixing a 5 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 5 mg/mL | 500 mcg | 50 mcg |
| 2 mL | 2.5 mg/mL | 250 mcg | 25 mcg |
| 3 mL | 1.667 mg/mL | 166.7 mcg | 16.67 mcg |
| 5 mL | 1 mg/mL | 100 mcg | 10 mcg |
Doses studied in research Approved drug
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
Adults: 0.75 mg subcutaneously once weekly; after 4 weeks the label allows an increase to 1.5 mg once weekly, then 1.5 mg increments after at least 4 weeks at each dosage; maximum 4.5 mg once weekly. Pediatric (10+ years): 0.75 mg once weekly, maximum 1.5 mg once weekly after at least 4 weeks. (subcutaneous)
Official label| Who was studied | Dose given | How often | For how long | What happened | |
|---|---|---|---|---|---|
| adults aged 50+ with type 2 diabetes and prior cardiovascular disease or risk factors (REWIND) n = 9901 |
1.5 mg subcutaneous | once weekly | median 5.4 years follow-up | major cardiovascular events 12.0% vs 13.4% with placebo (HR 0.88); GI adverse events 47.4% vs 34.1% | PubMed |
| adults with type 2 diabetes on metformin (AWARD-11) n = 1842 |
1.5, 3.0 or 4.5 mg subcutaneous | once weekly | 52 weeks (primary endpoint 36 weeks) | HbA1c -1.54% (1.5 mg) vs -1.77% (4.5 mg); weight -3.0 vs -4.6 kg; nausea 13.4% / 15.6% / 16.4% | PubMed |
| adults with type 2 diabetes on metformin, head-to-head vs semaglutide (SUSTAIN 7) n = 1201 |
0.75 or 1.5 mg (vs semaglutide 0.5 or 1.0 mg) subcutaneous | once weekly | 40 weeks | HbA1c -1.1 / -1.4 points and weight -2.3 / -3.0 kg with dulaglutide 0.75 / 1.5 mg; semaglutide lowered both more | PubMed |
| adults with type 2 diabetes on an SGLT2 inhibitor (AWARD-10) n = 424 |
0.75 or 1.5 mg subcutaneous | once weekly | 24 weeks | HbA1c -1.21% / -1.34% vs -0.54% with placebo | PubMed |
| adults with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7) n = 577 |
0.75 or 1.5 mg (vs insulin glargine) subcutaneous | once weekly | 52 weeks | HbA1c -1.1% / -1.2% at 26 weeks, non-inferior to insulin glargine; eGFR higher than with glargine | PubMed |
| youths aged 10 to <18 with type 2 diabetes n = 154 |
0.75 or 1.5 mg subcutaneous | once weekly | 26 weeks plus 26-week extension | HbA1c -0.6 / -0.9 points vs +0.6 with placebo; no BMI difference | PubMed |
Approved prescription drug; the label schedule above is for the conditions listed. Doses above 1.5 mg were added to the label after AWARD-11.
What the research says
Dulaglutide (a once-weekly GLP-1 receptor agonist for type 2 diabetes) is supported by many large human RCTs showing improved blood-sugar control and, in the REWIND outcomes trial, a modest reduction in cardiovascular events; its weight-loss effect is smaller than semaglutide or tirzepatide, and gastrointestinal side effects are common.
Key papers ✓ 4~ 2? 2
-
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Humans9,901 peopleRandomizedPlacebo-controlledDouble-blindMedian follow-up 5.4 yearsMulticentre, double-blind, randomised placebo-controlled trial (REWIND), 371 sites in 24 countries
In 9901 people with type 2 diabetes followed 5.4 years, dulaglutide reduced major cardiovascular events (12.0% vs 13.4%; HR 0.88) but not all-cause mortality; GI adverse events 47.4% vs 34.1%.
Key resultPrimary outcome in 594 (12.0%) dulaglutide vs 663 (13.4%) placebo participants (HR 0.88, 95% CI 0.79-0.99; p=0.026). GI adverse events 47.4% vs 34.1% (p<0.0001).
Study details
- Studied
- Adults aged 50+ with type 2 diabetes and previous cardiovascular event or risk factors (mean age 66.2 years)
- Compared with
- Placebo
- Main outcome
- First non-fatal MI, non-fatal stroke, or cardiovascular death
- Sample
- 9901 randomized (dulaglutide 4949, placebo 4952)
- Authors' conclusion
- Dulaglutide could be considered for glycaemic management in middle-aged and older people with type 2 diabetes with previous cardiovascular disease or risk factors. All-cause mortality did not differ significantly.
-
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.Humans424 peopleRandomizedPlacebo-controlledDouble-blind24 weeksPhase 3b double-blind, parallel-arm, placebo-controlled trial (AWARD-10)
In 424 people on SGLT2 inhibitors, adding dulaglutide lowered HbA1c by 0.66-0.79 points more than placebo at 24 weeks; nausea up to 15% vs 4%.
Key resultHbA1c fell more with dulaglutide 1.5 mg than placebo: LSM difference -0.79% (95% CI -0.97 to -0.61; p<0.0001); 0.75 mg difference -0.66% (-0.84 to -0.49; p<0.0001).
Study details
- Studied
- Adults with type 2 diabetes inadequately controlled on an SGLT2 inhibitor with or without metformin
- Compared with
- Placebo
- Main outcome
- Change in HbA1c at 24 weeks
- Sample
- 424 randomized (142 dulaglutide 1.5 mg, 142 dulaglutide 0.75 mg, 140 placebo)
- Authors' conclusion
- Dulaglutide added to SGLT2 inhibitors gave significant, clinically relevant glycaemic improvement with acceptable tolerability, mainly more gastrointestinal adverse events.
- Limitations
- 24-week duration.
-
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.Humans577 peopleRandomizedOpen-label52 weeks (primary outcome at 26 weeks)Multicentre, open-label randomised trial (AWARD-7); dulaglutide doses masked
In 577 people with type 2 diabetes and moderate-severe kidney disease, dulaglutide matched insulin glargine for HbA1c and showed slower eGFR decline and less hypoglycemia, but more nausea (up to 20%) and diarrhea (up to 17%).
Key resultAt 26 weeks LSM HbA1c change was -1.2% with dulaglutide 1.5 mg, -1.1% with 0.75 mg and -1.1% with insulin glargine; both doses were non-inferior. Symptomatic hypoglycaemia was lower with dulaglutide.
Study details
- Studied
- Adults with type 2 diabetes and stage 3-4 chronic kidney disease
- Compared with
- Daily insulin glargine, all with insulin lispro
- Main outcome
- HbA1c at 26 weeks (non-inferiority margin 0.4%)
- Sample
- 577 randomized (193, 190 and 194 per arm)
- Authors' conclusion
- Once-weekly dulaglutide gave glycaemic control similar to insulin glargine with reduced decline in eGFR, and seems safe in moderate-to-severe CKD.
- Limitations
- Open-label for insulin glargine comparison.
-
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.Humans1,201 peopleRandomizedOpen-label40 weeksOpen-label, parallel-group, phase 3b trial (SUSTAIN 7)
In 1201 people with type 2 diabetes, dulaglutide lowered HbA1c by 1.1-1.4 points and weight by 2.3-3.0 kg at 40 weeks, both significantly less than semaglutide; GI disorders in 33-48%.
Key resultHbA1c fell 1.8 points with semaglutide 1.0 mg vs 1.4 with dulaglutide 1.5 mg (ETD -0.41; p<0.0001); bodyweight fell 6.5 kg vs 3.0 kg.
Study details
- Studied
- Adults with type 2 diabetes inadequately controlled on metformin monotherapy
- Compared with
- Dulaglutide 0.75 mg or 1.5 mg
- Main outcome
- Change in HbA1c and bodyweight at week 40
- Sample
- 1201 randomized to four arms
- Authors' conclusion
- At low and high doses, semaglutide was superior to dulaglutide for glycaemic control and weight reduction, with a similar safety profile.
- Limitations
- Open-label; sponsored by Novo Nordisk (maker of semaglutide).
-
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.Humans13k peopleRandomizedDouble-blindActive-comparator, double-blind noninferiority trial (SURPASS-CVOT)
In 13,165 patients with type 2 diabetes and atherosclerotic disease, major cardiovascular events occurred in 13.1% on dulaglutide vs 12.2% on tirzepatide (tirzepatide noninferior, not superior).
Key resultPrimary event in 801 (12.2%) tirzepatide vs 862 (13.1%) dulaglutide patients (HR 0.92; 95.3% CI 0.83 to 1.01; P = 0.003 noninferiority; P = 0.09 superiority).
Study details
- Studied
- Adults with type 2 diabetes and atherosclerotic cardiovascular disease
- Compared with
- Dulaglutide 1.5 mg weekly
- Main outcome
- Composite of cardiovascular death, myocardial infarction or stroke
- Sample
- 13,299 randomized; modified ITT 6586 tirzepatide and 6579 dulaglutide
- Authors' conclusion
- Tirzepatide was noninferior to dulaglutide for the composite of cardiovascular death, MI or stroke; more gastrointestinal adverse events occurred with tirzepatide.
- Limitations
- Superiority not shown.
-
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.Humans154 peopleRandomizedPlacebo-controlledDouble-blind26 weeks (plus 26-week open-label extension)Double-blind, placebo-controlled trial (AWARD-PEDS) followed by open-label extension
In 154 youths with type 2 diabetes, dulaglutide lowered HbA1c by 0.6-0.9 points at 26 weeks while placebo rose 0.6, with no difference in BMI and more GI adverse events.
Key resultHbA1c rose 0.6 points with placebo and fell 0.6 (0.75 mg) and 0.9 (1.5 mg) points with dulaglutide (P<0.001 for both vs placebo); HbA1c <7.0% in 51% vs 14% (P<0.001).
Study details
- Studied
- Youths with type 2 diabetes, BMI above 85th percentile
- Compared with
- Placebo
- Main outcome
- Change from baseline in HbA1c at 26 weeks
- Sample
- 154 randomized participants aged 10 to <18 years
- Authors' conclusion
- Once-weekly dulaglutide 0.75 mg or 1.5 mg was superior to placebo for glycemic control through 26 weeks in youths with type 2 diabetes, without an effect on BMI.
- Limitations
- GI adverse events more frequent with dulaglutide.
-
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.Humans9,901 peopleRandomizedPlacebo-controlledDouble-blindMedian follow-up 5.4 yearsExploratory analysis of a randomised, double-blind, placebo-controlled trial
Exploratory REWIND analysis: substantive cognitive impairment was not significantly reduced in the main analysis (HR 0.93) but was 14% lower after post-hoc adjustment.
Key resultCognitive outcome HR 0.93 (95% CI 0.85-1.02; p=0.11); after post-hoc adjustment for baseline scores HR 0.86 (0.79-0.95; p=0.0018).
Study details
- Studied
- REWIND participants aged 50+ with type 2 diabetes and cardiovascular risk factors
- Compared with
- Placebo
- Main outcome
- First substantive decline on MoCA or DSST (1.5 SD or more below baseline)
- Sample
- 9901 randomized; 8828 had cognitive scores
- Authors' conclusion
- Long-term dulaglutide might reduce cognitive impairment in type 2 diabetes; further studies focused on brain health are indicated.
- Limitations
- Exploratory analysis; primary cognitive outcome was not significant before post-hoc adjustment.
-
Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.Humanssize not reportedPopulation-based new-user, active-comparator cohort study with propensity score matching
In large matched real-world cohorts, risk of severe GI events (pancreatitis, biliary disease, bowel obstruction, gastroparesis, severe constipation) was similar for dulaglutide, semaglutide and tirzepatide.
Key resultHR for severe GI events was 0.96 (95% CI 0.87 to 1.06) semaglutide vs dulaglutide and 0.96 (0.77 to 1.20) tirzepatide vs dulaglutide.
Study details
- Studied
- Adults with type 2 diabetes starting dulaglutide, semaglutide or tirzepatide (2019-2024)
- Compared with
- Pairwise: dulaglutide, subcutaneous semaglutide, tirzepatide
- Main outcome
- Composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, severe constipation
- Sample
- Matched pairs: 65 238 (semaglutide vs dulaglutide), 20 893 (tirzepatide vs dulaglutide), 46 620 (tirzepatide vs semaglutide)
- Authors' conclusion
- Dulaglutide, semaglutide and tirzepatide have similar gastrointestinal safety profiles in adults with type 2 diabetes.
- Limitations
- Possible residual confounding by glycemic control and BMI.
Reported side effects
- commonNausea [ref] [ref]
- commonDiarrhea and vomiting [ref] [ref]
- commonGastrointestinal adverse events overall [ref] [ref] [ref]
- rareSevere hypoglycemia [ref]
Severe GI complications such as pancreatitis or bowel obstruction were similar in frequency to semaglutide and tirzepatide in one large observational study.
95 registered human trials (12 active)
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Registered clinical trials 95 on ClinicalTrials.gov · 12 active · 72 completed · 39 with posted results
All 95 Dulaglutide trials, with countries and summaries · Search ClinicalTrials.gov · Recruiting trials for every peptide
Discussions elsewhere
Experiences and questions about Dulaglutide on other sites. Treat anecdotes with care.
Dulaglutide: questions people ask
What is Dulaglutide?
GLP-1 receptor agonist (weekly). A once-weekly GLP-1 analog used for blood-sugar control, with demonstrated cardiovascular benefit.
How much does Dulaglutide cost?
The cheapest Dulaglutide from an independently tested vendor is $2.09 per mg (Huatai Peptide, Dulaglutide 10Bottlex10mg, $209.00). Across 4 listings from 2 vendors the median is $2.90 per mg.
Where can I buy Dulaglutide?
2 vendors tested by Finnrick sell Dulaglutide. The cheapest per mg right now: Huatai Peptide ($2.09), Hangzhou Youngpeptide Biotechnology HYB ($2.90). 0 of them publish a lab report (COA) for Dulaglutide; compare lab scores and reports in the table above before buying.
How much bacteriostatic water for 5 mg of Dulaglutide?
Adding 2 mL of bacteriostatic water to a 5 mg vial of Dulaglutide gives 2.5 mg/mL: each 10 units on a U-100 insulin syringe holds 250 mcg. With 1 mL it's 5 mg/mL (500 mcg per 10 units); with 3 mL, 1.667 mg/mL (166.7 mcg per 10 units). More water makes small amounts easier to measure. Mixing charts: 5 mg, 10 mg.
Is Dulaglutide FDA approved?
FDA-approved as Trulicity (type 2 diabetes).
Can Dulaglutide be compounded in the US?
FDA-approved (Trulicity). It's a biologic-sized fusion protein; compounded versions aren't a recognised option. Compounding status for every peptide.
Does Dulaglutide work? What does the research say?
Evidence grade A (strong human evidence), from 8 papers: Approved drug; many large RCTs (incl. the 9,901-person REWIND trial) consistently show better glucose control and fewer cardiovascular events. Dulaglutide (a once-weekly GLP-1 receptor agonist for type 2 diabetes) is supported by many large human RCTs showing improved blood-sugar control and, in the REWIND outcomes trial, a modest reduction in cardiovascular events; its weight-loss effect is smaller than semaglutide or tirzepatide, and gastrointestinal side effects are common. See the papers.
Are there clinical trials of Dulaglutide?
ClinicalTrials.gov lists 95 registered trials of Dulaglutide: 12 active, 72 completed, 27 in phase 3, 39 with posted results. Examples: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (Active, not recruiting, Phase 3, 600 people); A Phase 3 Study of HS-20094 in Patients With T2DM (Not yet recruiting, Phase 3, 546 people); Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease (Not yet recruiting, Phase 4, 468 people).
What dose of Dulaglutide was used in studies?
Dulaglutide is an approved drug. Trulicity: Adults: 0.75 mg subcutaneously once weekly; after 4 weeks the label allows an increase to 1.5 mg once weekly, then 1.5 mg increments after at least 4 weeks at each dosage; maximum 4.5 mg once weekly. Pediatric (10+ years): 0.75 mg once weekly, maximum 1.5 mg once weekly after at least 4 weeks.; adults aged 50+ with type 2 diabetes and prior cardiovascular disease or risk factors (REWIND): 1.5 mg once weekly; adults with type 2 diabetes on metformin (AWARD-11): 1.5, 3.0 or 4.5 mg once weekly. These are amounts used in published studies or official labels, not a recommendation.
What are the side effects of Dulaglutide?
Reported in the research: Nausea; Diarrhea and vomiting; Gastrointestinal adverse events overall; Severe hypoglycemia. Severe GI complications such as pancreatitis or bowel obstruction were similar in frequency to semaglutide and tirzepatide in one large observational study.